NewEdge Advisors LLC Has $551,000 Position in Charles River Laboratories International, Inc. $CRL

NewEdge Advisors LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1,119.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,195 shares of the medical research company’s stock after purchasing an additional 2,933 shares during the quarter. NewEdge Advisors LLC’s holdings in Charles River Laboratories International were worth $551,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in CRL. Los Angeles Capital Management LLC bought a new position in Charles River Laboratories International in the 4th quarter valued at approximately $42,000. Sfam LLC bought a new stake in shares of Charles River Laboratories International during the fourth quarter worth $43,000. Activest Wealth Management grew its stake in shares of Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after buying an additional 218 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth $46,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director James C. Foster sold 28,733 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $275.00, for a total transaction of $7,901,575.00. Following the completion of the transaction, the director directly owned 31,596 shares in the company, valued at $8,688,900. This trade represents a 47.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria L. Creamer sold 4,179 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total value of $1,083,029.64. Following the completion of the transaction, the executive vice president directly owned 30,051 shares in the company, valued at approximately $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 132,429 shares of company stock valued at $32,538,088. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $295.23 on Friday. The stock has a market cap of $14.09 billion, a price-to-earnings ratio of -60.87, a P/E/G ratio of 3.02 and a beta of 1.38. Charles River Laboratories International, Inc. has a twelve month low of $144.26 and a twelve month high of $299.32. The company’s fifty day moving average is $234.99 and its 200 day moving average is $193.86. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.Charles River Laboratories International’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the company earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11.35 EPS for the current year.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River is collaborating with Medigen Vaccine Biologics to advance vaccine-development programs using next-generation sequencing. The partnership could expand CRL’s support for biologics and vaccine customers, although financial terms were not disclosed. Charles River Labs and Medigen Vaccine collaboration
• Positive Sentiment: Analysts highlight DSA’s return to organic growth, stronger bookings, and new testing capabilities as key drivers behind CRL’s approximately 88.6% one-year advance. These trends support the company’s strategy of broadening its role in drug-development services. Charles River rally drivers
• Neutral Sentiment: Options-market activity suggests traders are positioning for a potentially significant move in CRL shares, but the activity does not establish whether the anticipated move will be upward or downward. CRL options activity
• Negative Sentiment: Zacks cautions that the recent 33.3% monthly surge has raised the bar for execution. Margin pressure and a premium valuation may constrain upside unless bookings and guidance continue to improve. CRL valuation and rally outlook
• Negative Sentiment: Director Nancy Andrews sold 573 shares for approximately $163,443, reducing her direct holdings by 28.5%. The transaction is modest but adds to investor focus on insider selling after the stock’s rally. Nancy Andrews insider sale
• Negative Sentiment: EVP Shannon M. Parisotto sold 2,039 shares for approximately $599,711, reducing direct ownership by 29.8%; the sale was made under a pre-arranged Rule 10b5-1 trading plan, which lessens its signaling value. Shannon Parisotto insider sale

Analyst Ratings Changes

CRL has been the topic of several recent research reports. CLSA downgraded Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective on the stock. in a report on Monday, July 20th. Mizuho set a $264.00 target price on Charles River Laboratories International in a report on Monday, August 10th. Evercore reiterated an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. Robert W. Baird set a $291.00 price target on Charles River Laboratories International in a research note on Thursday, August 6th. Finally, Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $255.65.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.